Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.67 |
| ▸ | BCR | P11274 | 8/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837361 | 0.94 | ABL1 (0.74) | ABL1BCRTRPV1EPHX2 | |
| SCHEMBL1012120 | 0.91 | TRPV1 (0.63) | ABL1BCRTRPV1 | |
| SCHEMBL1011247 | 0.89 | ABL1 (0.61) | ABL1BCRTRPV1FGFR2FLT3 | |
| SCHEMBL1013494 | 0.83 | ABL1 (0.60) | ABL1BCRTRPV1KDR | |
| SCHEMBL1013803 | 0.81 | TRPV1 (0.75) | ABL1BCRTRPV1FAAH | |
| SCHEMBL3425763 | 0.80 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL1013351 | 0.80 | TRPV1 (0.63) | ABL1BCRTRPV1EGFRFAAH | |
| SCHEMBL1013008 | 0.79 | TRPV1 (0.62) | ABL1BCRTRPV1FAAH | |
| SCHEMBL1014091 | 0.78 | ABL1 (0.70) | ABL1BCRTRPV1FAAH | |
| SCHEMBL1011253 | 0.77 | TRPV1 (0.83) | ABL1BCRTRPV1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | claimed |
| US-7053088-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-05-30 | — | — | US | claimed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | claimed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7053088-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005070072-A2 | RECIPROCAL REGULATION OF INFLAMMATION AND LIPID METABOLISM BY LIVER X RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040259948-A1 | Liver receptors as antiinflammatory agents and for immunity with administering agonist | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-12-23 | — | — | US | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259948-A1 | Liver receptors as antiinflammatory agents and for immunity with administering agonist | NR1H3, NR1H2, NR1H4 | ABL1 4544/4885BCR 3274/4885TRPV1 1065/4885 |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ABL1 1496/4885BCR 630/4885TRPV1 1/4885 |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ABL1 1443/4885BCR 587/4885TRPV1 1/4885 |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ABL1 1443/4885BCR 587/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.